ストックスクリーナーアプリを入手
8.76
3.10%
-0.28
プレマーケット:
8.77
0.010
+0.11%
Entrada Therapeutics Inc (TRDA) 最新ニュース
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - Defense World
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks
Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK
Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks
Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha
Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView
Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech
Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia
Entrada Therapeutics begins Duchenne study in UK - Investing.com India
Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times
Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan
Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com
Entrada Therapeutics CFO sells $19,035 in stock By Investing.com - Investing.com South Africa
Entrada Therapeutics CFO sells $19,035 in stock - Investing.com India
Long Term Trading Analysis for (TRDA) - news.stocktradersdaily.com
Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia
Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World
Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada
Brokers Offer Predictions for TRDA Q4 Earnings - Defense World
What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Yahoo
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
Entrada Therapeutics' (TRDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year - TipRanks
Oppenheimer maintains Entrada stock Outperform with $30 target - Investing.com
Oppenheimer maintains Entrada stock Outperform with $30 target By Investing.com - Investing.com South Africa
Entrada Therapeutics Reports Strong 2024 Financial Results - TipRanks
Entrada Therapeutics earnings beat by $0.70, revenue fell short of estimates - Investing.com UK
Entrada Therapeutics sees cash runway into 2Q27 - TipRanks
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Allspring Global Investments Holdings LLC Lowers Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments - TipRanks
FDA authorizes Entrada’s DMD drug study By Investing.com - Investing.com Australia
Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials - TipRanks
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy - Benzinga
Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket - Marketscreener.com
Entrada rises as FDA removes clinical hold on muscle-wasting therapy - TradingView
FDA authorizes Entrada's DMD drug study - Investing.com India
FDA authorizes Entrada’s DMD drug study - Investing.com
Entrada Therapeutics Receives FDA Approval for DMD Study - TipRanks
FDA authorizes Entrada's DMD drug study By Investing.com - Investing.com South Africa
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - The Manila Times
Entrada announces FDA removal of clinical hold on ENTR-601-44 - TipRanks
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):